<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01403025</url>
  </required_header>
  <id_info>
    <org_study_id>NN2211-3772</org_study_id>
    <secondary_id>U1111-1120-7575</secondary_id>
    <secondary_id>JapicCTI-111559</secondary_id>
    <nct_id>NCT01403025</nct_id>
  </id_info>
  <brief_title>Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes</brief_title>
  <official_title>A Multi-centre, Open Label, Observational, Non-interventional Study to Evaluate the Safety and Effectiveness of Victoza® in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Asia. The aim of the trial is to assess the incidence rate and
      type of SADRs (serious adverse drug reactions).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 19, 2011</start_date>
  <completion_date type="Actual">December 28, 2015</completion_date>
  <primary_completion_date type="Actual">December 28, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of SADRs (Serious Adverse Drug Reactions)</measure>
    <time_frame>After 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence rate and type of SAEs (Serious Adverse Events)</measure>
    <time_frame>At month 1, 3, 6, 12, 24 and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence rate and type of ADRs (Adverse Drug Reactions)</measure>
    <time_frame>At month 1, 3, 6, 12, 24 and 36</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">4121</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Once daily at a fixed timing, and subcutaneously (under the skin) in the abdomen, in the thigh or in the upper arm</description>
    <arm_group_label>Liraglutide</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with type 2 diabetes mellitus, including newly-diagnosed subjects, who are
        considered to need treatment with liraglutide (Victoza®)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with type 2 diabetes mellitus, including newly-diagnosed subjects, who
             require treatment with liraglutide

        Exclusion Criteria:

          -  Subjects who are or have previously been on liraglutide

          -  Subjects who have previously been enrolled in the study

          -  Subjects with a hypersensitivity to liraglutide or to any of the excipients

          -  Subjects who are pregnant, breast feeding or have the intention of becoming pregnant
             within the study periods

          -  Subjects with cancer (except basal cell skin cancer or squamous cell skin cancer) or
             any clinically significant disorder, except for conditions associated with type 2
             diabetes mellitus history which in the physicians' opinion could interfere with the
             results of the trial

          -  Known or suspected abuse of alcohol or narcotics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>1000005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2011</study_first_submitted>
  <study_first_submitted_qc>July 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2011</study_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

